
The End of the Welfare State

Basic Research

Paul Volders, MD, PhD, FESC








No financial interests to disclose




Government Funding of Medical Science Performed by the Academic and Non-Profit Sectors; Share of GDP








Growth in Total Health Expenditure Per Capita









The End of the Welfare State





NIH Appropriation; Share of GDP / Grant Application Success Rates









Additional International Developments

- Intensified global competition: China, Germany, India, Singapore, Sweden, United Kingdom, and other countries have recognized that life sciences represent a high-wage, high-growth industry
- Some of these countries not only <u>expended financial</u> <u>support for biomedical research</u>, but also implemented tax incentives, regulatory reforms to speed drug approvals, and immigration and education policies to attract the best lifesciences talent
- E.g., China has identified biotechnology as one of seven key strategic and emerging pillar industries, and has pledged to invest \$308.5 billion in the period 2012-2017






Phenomenal Challenges That Require Strong Basic-Science and Translational Research







Phenomenal Challenges That Require Strong Basic-Science and Translational Research










Additional challenges ...









Consequent developments, examples from the UK and NL




The Netherlands Cardio Vascular Research Initiative

Steering towards synergy and impact.



From







The Netherlands CardioVascular Research Initiative

Steering towards synergy and impact.



Successful when:

- The best basic and clinical cardiovascular scientists in a country collaborate in integrated research consortia, elucidating mechanisms underlying CV diseases and solving problems in patient care
- The PIs in these consortia have succeeded in establishing integrated research programs that are more than the management of individual projects

The Netherlands Cardio Vascular Research Initiative


Steering towards synergy and impact.



- The projects are innovative and internationally competitive
- The principle investigators foster new developments and young talent
- The consortia are successful in acquiring leadership in European programs



Consequent developments, other example







Thank you!

Paul Volders, MD, PhD, FESC

p.volders@maastrichtuniversity.nl







Slide title here with space for two lines of text

Conclusion: There are good reasons to pursue academic research.

However, academic research is more of a gift economy than an economic growth policy, at least for rich countries. Richer countries can afford to do more academic research, but academic research is not what makes you rich (I should know!).

government R&D alone can often reach 1% of the GDP.

The problem is that it is private R&D that contributes to economic growth, not government R&D:



Demographic alterations

- Europe is losing 700,000 people each year, and will lose 3 million more each year by 2050
- Older citizens are making up a larger and larger share of the declining population
- E.g., there were nearly 500 million people around the globe aged ≥65 years in 2012. By 2030, this number is expected to double to 1 billion, or 1 in 8 people
- Ratio of European working-age: elderly citizens expected to be down to 2: 1 by 2050



Genetic era


- 60% of all people will, at some time in their life, be affected by the consequences of a gene mutation
- 71% of admissions to a major U.S. pediatric hospital have an underlying genetic basis
- Only 1% of genetic disorders are diagnosed at birth
- This enables early detection of disease susceptibility by genomic sequencing

Slide title here with space for two lines of text

Epidemic of heart failure and related arrhythmic problems

Wearable and implantable devices; telemetric medicine

In Billions of 2008 Dollars







Phenomenal Challenges That Require Strong Basic-Science and Translational Research

Adult stem-cell therapy, pluripotency

Complex genomics; fast, low-cost human genomes are transforming our lives; at least 80% of the so-called junk DNA functionary to the so-called "superbugs" to existing drugs; need to evelop new, more powerful ABs

Demand for customized and treatment therapies rises rapidly as personalized medicine trend accelerates







Slide title here with space for two lines of text


Personalized medicine: practice of medicine based on the indvidual patient, rather than a statistical sample. Devising customized therapies that take advanatge of inidiviual pat's genetic makeup and unique pathology







Slide title here with space for two lines of text



Science faces crisis of trust

Harnessing the big data opportunity







Slide title here with space for two lines of text

Epidemic of heart failure and related arrhythmic problems

Wearable and implantable devices; telemetric medicine

